VBCG
REGN icon

Valley Brook Capital Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Valley Brook Capital Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-100
Closed -$47K – 359
2021
Q1 		$47K Hold
100
– – 0.04% 229
2020
Q4 		$48K Buy
+100
New +$54K 0.05% 202

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Valley Brook Capital Group's REGN Position: Q2 2021 in Review

Valley Brook Capital Group sold out of Regeneron Pharmaceuticals (REGN) in Q2 2021, closing a stake of 100 shares — an estimated $47K sold.

Valley Brook Capital Group first reported a position in REGN in Q4 2020 and held it in 2 quarters. The position peaked at $48K in Q4 2020. 971 funds tracked by Wall St. Rank hold REGN as of Q2 2021.

  • Valley Brook Capital Group reported no remaining Regeneron Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Valley Brook Capital Group sold 100 Regeneron Pharmaceuticals shares in Q2 2021, an estimated $47K.
  • Valley Brook Capital Group first reported a position in Regeneron Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Valley Brook Capital Group's Regeneron Pharmaceuticals position peaked at $48K in Q4 2020.
  • 971 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2021.

Based on Valley Brook Capital Group's 13F filing for Q2 2021, filed 22 Jul 2021.